Discounted Cash Flow
Sarepta Therapeutics, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $5.4m | $-267.3m | $-251.2m | -4930.2% | — |
| 2017 | $154.6m (2751.6%) | $-50.7m (81.0%) | $-244.0m (2.9%) | -32.8% (99.3%) | — |
| 2018 | $301.0m (94.7%) | $-361.9m (-614.0%) | $-449.8m (-84.4%) | -120.2% (-266.7%) | — |
| 2019 | $380.8m (26.5%) | $-715.1m (-97.6%) | $-516.1m (-14.7%) | -187.8% (-56.2%) | — |
| 2020 | $455.9m (19.7%) | $-554.1m (22.5%) | $25.3m (104.9%) | -121.6% (35.3%) | — |
| 2021 | $612.4m (34.3%) | $-418.8m (24.4%) | $-481.7m (-2006.5%) | -68.4% (43.7%) | $-5.15 |
| 2022 | $843.8m (37.8%) | $-703.5m (-68.0%) | $-356.2m (26.1%) | -83.4% (-21.9%) | $-8.03 (-55.9%) |
| 2023 | $1.2b (47.4%) | $-536.0m (23.8%) | $-577.1m (-62.0%) | -43.1% (48.3%) | $-5.80 (27.8%) |
| 2024 | $1.9b (53.0%) | $235.2m (143.9%) | $-342.7m (40.6%) | 12.4% (128.7%) | $2.47 (142.6%) |
| 2025 | $2.2b (15.6%) | $-713.4m (-403.3%) | $-307.5m (10.3%) | -32.5% (-362.4%) | $-7.13 (-388.7%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.